Adicet Bio AI Stock Analysis
Want to see ACET full AI Analyst Report?
Adicet Bio (ACET) AI Stock Analysis
Adicet Bio
(NASDAQ:ACET)
The score is held down primarily by weak financial performance (no revenue, large losses, and significant cash burn) and very bearish technicals (price far below major moving averages with negative momentum). Offsetting these, corporate events provide some support via positive clinical/regulatory progress and upcoming pipeline catalysts, but valuation is not supportive given continued unprofitability and no dividend.
Adicet Bio (ACET) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $26.03M
- Dividend Yield
- ―
- Average Volume (3M)
- 233.09K
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 1.92
- Revenue Growth
- ―
- EPS Growth
- 57.60%
- Country
- US
- Employees
- 102
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Adicet Bio Business Overview & Revenue Model
Company Description
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen recepto...
How the Company Makes Money
Adicet Bio does not have publicly established, recurring product revenue from marketed drugs (null for product sales), because it is a clinical-stage biotechnology company without approved commercial products. The company’s funding and revenue, when...
Adicet Bio Financial Statement Overview
Summary
Operating fundamentals are very weak: recent periods show $0 revenue, large ongoing net losses (about -$91.0M TTM), and persistent cash burn (operating cash flow about -$80.1M TTM; free cash flow about -$80.4M). The main offset is a relatively conservative balance sheet with low leverage (debt-to-equity ~0.12), though the equity base has shrunk materially over time.
Income Statement
18Very NegativeBalance Sheet
58NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 24.99M | 9.73M |
| Gross Profit | -1.34M | -6.38M | 0 | 0 | 24.99M | 9.73M |
| EBITDA | -85.04M | -110.39M | -110.65M | -136.53M | -67.04M | -60.41M |
| Net Income | -91.00M | -116.80M | -117.12M | -142.66M | -69.79M | -62.00M |
Balance Sheet | ||||||
| Total Assets | 128.95M | 192.35M | 220.22M | 207.29M | 330.69M | 338.94M |
| Cash, Cash Equivalents and Short-Term Investments | 100.94M | 158.53M | 176.30M | 159.71M | 257.66M | 277.54M |
| Total Debt | 12.10M | 14.74M | 17.23M | 20.92M | 21.02M | 20.94M |
| Total Liabilities | 26.25M | 33.15M | 33.61M | 37.12M | 38.35M | 35.81M |
| Stockholders Equity | 102.70M | 159.21M | 186.61M | 170.18M | 292.34M | 303.13M |
Cash Flow | ||||||
| Free Cash Flow | -80.43M | -96.98M | -93.50M | -98.18M | -61.55M | -64.10M |
| Operating Cash Flow | -80.14M | -95.25M | -92.38M | -93.72M | -44.77M | -51.05M |
| Investing Cash Flow | 2.60M | 2.39M | -119.24M | -4.46M | -16.78M | -2.80M |
| Financing Cash Flow | 75.23M | 75.25M | 111.31M | 236.00K | 41.51M | 242.69M |
Adicet Bio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Negative. The current price of 2.78 is below the 20-day moving average (MA) of 3.52, below the 50-day MA of 5.93, and below the 200-day MA of 7.43, indicating a bearish trend. The MACD of -0.83 indicates Negative momentum. The RSI at 17.54 is Positive, neither overbought nor oversold. The STOCH value of 12.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACET.
Adicet Bio Risk Analysis
Adicet Bio disclosed 24 risk factors in its most recent earnings report. Adicet Bio reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAdicet Bio Peers Comparison
Overall Rating
IMMX51Neutral
ACET42Neutral
STRO42Neutral
GANX41Neutral
PMVP41Neutral
ARTV40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $657.09M | -9.45 | -24.93% | ― | ― | -5.65% | |
| 42Neutral | $26.03M | -0.32 | -69.71% | ― | ― | 57.60% | |
| 42Neutral | $163.03M | -0.78 | 142.71% | ― | -57.30% | 51.45% | |
| 41Neutral | $46.31M | -2.48 | -133.17% | ― | ― | 33.17% | |
| 41Neutral | $95.93M | -0.82 | -110.22% | ― | ― | 3.11% | |
| 40Underperform | $198.22M | -1.34 | -45.32% | ― | ― | 7.78% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ACET | Adicet Bio Inc | 2.78 | -6.84 | -71.10% | |
| STRO | Sutro Biopharma | 9.82 | 0.92 | 10.34% | |
| PMVP | Pmv Pharmaceuticals, Inc. | 1.27 | -0.13 | -9.29% | |
| GANX | Gain Therapeutics, Inc. | 1.04 | -1.81 | -63.51% | |
| IMMX | Immix Biopharma, Inc. | 7.84 | 3.59 | 84.47% | |
| ARTV | Artiva Biotherapeutics, Inc. | 4.01 | 0.12 | 3.08% |
Adicet Bio Corporate Events
Adicet Bio Advances Prula-cel Toward Pivotal Lupus Trial
PositiveOn September 28, 2026, Adicet Bio reported Phase 1 data for its investigational therapy prula-cel in 22 patients with systemic lupus erythematosus, including 16 with lupus nephritis, with follow-up ranging from six to 21 months. At 12 months, 50% of...
Adicet Bio Highlights Prula-cel Autoimmune CAR-T Pipeline Progress
PositiveOn September 8, 2026, Adicet Bio posted an investor presentation outlining progress and key milestones across its pipeline of allogeneic gamma-delta1 CAR-T and in vivo CAR-T therapies, emphasizing prula-cel as a potential first off-the-shelf, one-tim...
Adicet Bio completes prula-cel Phase 1 SLE analysis
PositiveOn September 1, 2026, Adicet Bio reported completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in systemic lupus erythematosus patients, with or without lupus nephritis, with t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
